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Background: To investigate the effects of statin use over the last 10 years among diabetic patients 
who initiated glucose-lowering medications (GLMs) in Denmark. Methods: we identified all Danish 
citizens 30 years and older who claimed their first GLM between 1997 and 2006, with follow-up 
until 2007 . Use of medications, national background, income, and hospitalizations were obtained 
by cross-linkage of national registries in Denmark. We analyzed factors related to initiation and 
interruption of statin treatment. The analyses included country of birth, citizenship and, as proxy for 
ethnic origin, we constructed variables based on both the subjects and on their parent’s country 
of birth. Countries were grouped as Denmark, Western countries, Eastern countries, and Africa. 
Results: the cohort included 143,625 subjects. Compared with persons of Danish origin, the 
initiation of a statin medication during follow-up was significantly lower among patients of non-
Danish origin: Odds ratio for subjects of Eastern origin 0.61 [CI 0.49–0.76] and 0.37 for subjects 
of African origin, [CI 0.24–0.59], both p < 0.001. The risk of interrupting statin treatment once it 
had been initiated was also higher in these groups (hazard ratio 2.03, [CI 1.91–2.17] for Eastern 
subjects and 1.94, [CI 1.63–2.32] for African subjects, both p < 0.0001). Combination of ethnic 
parameters to refine identification of the cohort led to the same conclusions as the analysis based 
only on country of birth or citizenship respectively. Conclusion: diabetes patients of African and 
Eastern origin in Denmark have less chance of being treated with a statin than those of western 
and Danish origin despite similar access to the Danish health care system.
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statins over the years (Dominguez et al., 2009). Given the increas-
ing size of the diabetic population (Christensen et al., 2009) it is 
important to identify subgroups that do not adhere to guideline 
recommendations, for which efforts can be targeted to improve 
this adherence.
Danish national registries provide a unique opportunity to elab-
orate proxy markers for ethnic background by combining family 
composition for a given individual.
Thus we have performed this study comparing different ethnic 
background parameters on initiation and persistence in treatment 
with statins among new users of glucose-lowering medications 
(GLMs) in Denmark between 1997 and 2006.
Materials and Methods
The study is based on cross-linkage of nationwide registries. 
All residents in Denmark are assigned a unique and permanent 
personal civil registration number at the Central Office of Civil 
Registration which enables cross-linkage of registries on the indi-
vidual level (WHO, 2007). From the data of the Central Office of 
introduction
Ethnic background has been demonstrated to have a profound effect 
on cardiovascular health parameters in North-American (Benner 
et al., 2002; Kaplan et al., 2004; Hertz et al., 2007; Cooper et al., 2009; 
McWilliams et al., 2009) and European epidemiological studies (Peters 
et al., 2009). In North-American studies, it has been demonstrated that 
even when differences in risk profiles such as socioeconomic status are 
equalized, clinical outcomes are still influenced by differences in ethnic 
background for African-Americans (Mayberry et al., 2000; Trivedi 
et al., 2006; Hozawa et al., 2007) and for Mexican Americans (Hertz 
et al., 2007). Nevertheless, ethnicity is a complex concept composed 
of biological and cultural elements that change over time. Therefore, 
it has been recently stressed the importance of defining parameters 
of ethnicity that give an appropriate understanding of variations in 
clinical outcomes by ethnicity and help issuing health policies and 
planning (Lee, 2009; Mladovsky, 2009; Rafnsson and Bhopal, 2009).
Statin treatment is recommended by international guidelines 
for almost all subjects with diabetes (NCEP, 2001; Ryden et al., 
2007). This recommendation has resulted in an increased use of 
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data existed, otherwise by the country of birth of the individual. 
Countries were grouped in four categories: (1) “Denmark”; (2) 
“Western countries” for European countries other than Denmark, 
including Baltic countries, America, and Oceania; (3) “Eastern 
countries” for all countries from the Asian continent, although 
including Turkey, and (4) “Africa” for all countries from the 
African continent.
To investigate secular trends over time, the 10 years follow-up 
was divided in three periods: (1) from 1997 to 2000; (2) from 2001 
to 2003, and (3) from 2003 to 2007. Use of GLMs was assessed upto 
the end of 2006. Subsequent commencement of statin treatment 
was followed upto the end of 2007, ensuring at least 1 year follow-up 
for the subjects who initiated GLM during 2006. Subjects were cen-
sored at the end of follow-up or if they emigrated from Denmark, 
regardless whether they returned to Denmark or not.
Adherence can be defined in different ways. Most often adher-
ence has been defined as the time-course until treatment is paused. 
Since many subjects who pause their medication after a myocardial 
infarction resume the treatment even after several months cessa-
tion (Gislason et al., 2006), we performed two analyses. Firstly we 
calculated the percentage of subjects receiving statins at any time-
point and secondly we analyzed the time until a break in treatment 
of 90 days or more occurred, as a dichotomous variable, as we have 
described in previous studies (Gislason et al., 2006; Dominguez 
et al., 2009).
This manuscript follows the strengthening the reporting of 
observational studies in epidemiology (STROBE) recommenda-
tions (von Elm et al., 2008). All authors have read and agreed to 
the manuscript as written.
statistical analysis
We performed a Cox proportional-hazards analysis to assess fac-
tors associated with initiation of statins according to ethnic origin, 
adjusting for year of first GLMs prescription claim (using the time 
period 1997 to 2000 as reference), age, sex, previous myocardial inf-
arction, previous stroke, insulin treatment as the first anti-diabetes 
Civil Registration it was possible to perform ethnic grouping by 
identifying place of birth of an individual and his/her parents, citi-
zenship and residence, as explained in detail below. Additionally, 
household income was recorded. The Danish National Patient 
Registry keeps records on all hospital admissions since 1978. 
Each admission is registered with one primary diagnosis, and if 
appropriate one or more secondary diagnoses, according to the 
International Classification of Diseases, the 8th revision until 
1994 (ICD-8) and the 10th revision (ICD-10) from 1994 (WHO, 
2004). Since 1995 all claimed prescriptions from pharmacies in 
Denmark have been registered in the Danish Registry of Medicinal 
Products Statistics. Drugs are classified according to the interna-
tional anatomical therapeutical chemical (ATC) system, and the 
registry also includes information on date of dispensing, dosage, 
quantity dispensed, and the affiliation of the physician issuing 
the prescription.
Danish national registries are centralized in Statistics Denmark 
where each individual civil registration number is encrypted by 
substituting it with another number that is the same in all regis-
tries, thereby allowing cross-linkage of encrypted data. Access to the 
data is granted to researchers upon registration in Danish registry. 
The protocol was reviewed by the Danish Ministry of Interior and 
Health and by the Danish Agency for Science, Technology, and 
Innovation.
The study cohort comprised all persons who claimed a prescrip-
tion for a GLM as a proxy for diabetes diagnosis between 1997 
and 2006. Persons who had purchased GLMs during 1996 were 
excluded. We then analyzed whether these persons subsequently 
claimed statins or not, hence including current statin users, with 
follow-up until the end of 2007. The period of days covered by a 
purchase of a statin was calculated based on the pack size purchased, 
and assuming an average dosage of one daily tablet, as we have 
described in previous studies (Gislason et al., 2006; Dominguez 
et al., 2009).
Subjects who had been hospitalized with a myocardial infarc-
tion as a primary diagnosis (ICD codes I21 or I22 and ICD-8 code 
410 for myocardial infarction before 1994) in the 19 year period 
before inclusion were identified as “previous myocardial infarc-
tion.” A prior stroke was identified in an analogous manner (ICD 
codes I63–I66 and IDC-8 code 432–436 for stroke before 1994). 
Occurrences of myocardial infarction or stroke during the study 
period were included as co-morbidities of interest. If a person had 
suffered both MI and stroke, the latest event prior to GLM initiation 
was included in the analyses.
Ethnicity parameters were analyzed combining data collected 
in the Central Office of Civil Registration. Country of birth and 
citizenship respectively were considered as simple ethnicity 
parameters. Furthermore, we sought to approach the effect of 
cultural legacy in our cohort by constructing a refined ethnicity 
proxy that we called “country of origin” based on the parent’s 
country of birth for a given individual (Figure 1). Accordingly, 
persons with a parent born in Denmark and holding Danish 
citizenship were categorized as being “of Danish origin” regard-
less of the place of birth of the given individual. Persons born 
in Denmark or abroad with parents not fulfilling Danish citi-
zenship were classified as “not of Danish origin.” The country 
of origin was determined by the mother’s country of birth if 
FiguRe 1 | Construction of “country of origin” as ethnicity proxy. 
“Country of origin” was based on the parent’s country of birth for a given 
subject. If one of the parents was born in Denmark and hold Danish 
citizenship, the person was classified as being of “Danish origin. ” When a 
person is identified as being of “non-Danish origin, ” the country of birth of the 
mother defines the person’s “country of origin. ” If data about the mother is 
not available in the national Danish registry, the country of birth of this person 
is taken as “country of origin. ”www.frontiersin.org  December 2010  | Volume 1  |  Article 142  |  3
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seem to influence the effect of a previous myocardial infarction or 
stroke on higher chance for the initiation of statins. Low income 
had some effect on initiation of statins with a 24% higher risk for 
the group with lowest income (p = 0.02; Table 2).
Between 85 and 95% of the Danish subjects who commenced 
treatment with statins, continued using statins throughout the fol-
lowing years, while a larger amount of subjects from other ethnic 
medicine and income graded in quartiles. Analyses were repeated 
for ethnic grouping based on citizenship and on country of birth, 
with the same covariates included in the models.
Model assumption for the proportional-hazard models 
(  proportional-hazard assumption, linearity of continuous vari-
ables, and lack of interaction) were tested and found valid unless 
otherwise indicated.
All statistical calculations were performed SAS statistical soft-
ware package, version 9.1 for UNIX servers (SAS Institute Inc., 
Cary, NC, USA).
results
In total, the cohort comprised 143,625 new users of GLMs from January 
1st 1997 to December 31st 2006. Baseline characteristics and the distri-
bution of the cohort according to their ethnic origin are shown in Table 
1. Subjects of Eastern and African origin were younger and less likely 
to have a previous history of myocardial infarction and/or stroke. The 
highest proportion of men was found among African subjects.
The chance of ever receiving statins was 39% lower among sub-
jects from Eastern origin and about 63% lower among subjects from 
African origin while it was 20% lower among subjects from Western 
origin compared to Danish subjects (Table 2). Analyses based on 
birth and on citizenship as unrefined ethnic parameters yielded 
similar results – data not shown. For the total cohort of GLMs 
users, there was a progressive increase in the use of statins, with a 
tendency over the years to reduce ethnic differences for subjects of 
Western and Eastern origin but not among Africans, as depicted in 
Figure 2. Since European and American guidelines updates encour-
aged a broader use of statins in subjects with diabetes (Wood et al., 
1998; NCEP, 2001), the 10 year follow-up is divided in Figure 2 
in two periods from 1997 to 2001 (Figure 2A) and from 2001 to 
2007 (Figure 2B). Multivariable analyses revealed no interaction 
between sex and the different ethnic groups on initiation of statins, 
or between country of origin and year of prescription.
A previous myocardial infarction or previous stroke increased 
the chance that GLMs users initiated statins more than twofold for 
myocardial infarction and by about 60% for stroke (Table 2). No 
interactions were observed in several models for ethnic origin and 
analyses by citizenship and by country of birth respectively yielded 
equivalent results (data not shown). Hence ethnic origin did not 
Table 1 | Distribution of the cohort of 143,625 subjects using glucose-lowering medications in Denmark in the period 1997–2006, according to ethnic 
origin.
  Country of origin
  Denmark  Western countries*  eastern countries*  Africa  Total
Total number of new glucose-lowering   131,669  4,458  6,549  949  143,625 
medications users
Age, years ± SD  58 ± 13  54 ± 13  47 ± 11  46 ± 10  58 ± 12
Men, %  56.5  50.8  55.4  65.5  56.3
Previous myocardial infarction, %  8.7  6.8  4.9  3.5  8.4
Previous stroke, %  7.9  5.3  2.7  2.1  7.6
Insulin, %   9.4  8.4  6.8  14.5  9.3
*Western countries include America, Oceania, Baltic countries, and Western Europe. Eastern countries include Asia and Turkey.
Table 2 | Cox proportional analysis on the proportion of subjects who 
initiated statin treatment after the first claimed prescription of 
glucose-lowering medicine.
  Hazard ratio  95% Ci  P
Age – per 10 year increment  0.98  0.92–1.01  0.4
Female sex*  1   
Male sex  1.08  0.95–1.22  0.4
1997–2000*  1  
2001–2003  2.06 1.89–2.23  <0.0001
2004–2006  2.15 2.04–2.26  <0.0001
No previous myocardial   1     
infarction or stroke*
Previous myocardial infarction  2.89  2.55–3.27  <0.0001
Previous stroke  1.36  1.14–1.62  0.0006
GLM other than insulin*  1   
Insulin treatment  0.63  0.53–0.77  <0.0001
CounTRy oF oRigin
 Denmark*  1   
  Western countries**  0.80  0.68–0.95  0.009
  Eastern countries**  0.61  0.49–0.76  <0.0001
 Africa  0.37  0.24–0.59  <0.0001
inCoMe
  Highest quartile*  1   
  Third quartile  0.96  0.83–1.12  0.6
  Second quartile  0.89  0.78–1.02  0.1
  Lowest quartile  0.76  0.64–0.91  0.002
*Reference in Cox regression analysis.
**Western countries include America, Oceania, Baltic countries, and Western 
Europe. Eastern countries include Asia and Turkey.Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology  December 2010  | Volume 1  |  Article 142  |  4
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 citizenship alone. By contrast, the Eastern and African  populations 
were robustly identified in all analyses as high risk populations for 
lack of initiation of statins (Table 2; Figure 2) as well as for inter-
rupting statin treatment (Table 3; Figures 3 and 4).
Our results are in agreement with findings in a British study that 
regards the use of health services among different ethnic groups 
(Peters et al., 2009). Our cohort of African subjects is approximately 
10 years younger than the rest of the population (Table 1) which 
may affect the results of the analyses. Nevertheless, in a previous 
study it has been observed that cardiovascular risk is increased in 
all persons over 30 years old using GLMs (Schramm et al., 2008). 
Furthermore, we cannot exclude that lipid levels among GLMs 
users from African origin are lower, but in the atherosclerosis risk 
origins discontinued statin (Figure 3). Multivariable Cox analyses 
were performed to elucidate which factors determined a poor long-
term use of statins (Table 3) and demonstrated an increased risk 
for discontinuing statin treatment, especially among subjects of 
Eastern and African origin. These analyses with refined parameters 
for ethnic origin yielded similar results to analyses using simple 
parameters as country of birth and citizenship (Figure 4). Income 
did not seem to have a strong effect on the risk to withhold statins, 
with only a highest risk of 7% for discontinuation for the group 
with lowest income (Table 3). Multivariable analyses revealed no 
interaction between sex and the different ethnic groups for the risk 
of interrupting statin treatment.
discussion
This nationwide study reveals important ethnic inequalities in 
Denmark among persons who have commenced using GLMs over 
a 10-year period, from 1996 to 2006. Persons with Eastern and 
African background are identified as a high risk group since they 
initiate statin treatment later, to a lesser extent and are at higher risk 
of discontinuing statin treatment than other ethnic groups.
The main strength of the study is the completeness of data, 
especially regarding systematic collection of the population living 
in Denmark and of all diabetes subjects receiving GLMs treatment 
on a nationwide level. It has been claimed that ethnic parameters 
used in published studies are often just one such as birth place or 
citizenship, or they are poorly defined (Lin and Kelsey, 2000; Ford 
and Kelly, 2005). In a review of European studies that addresses 
ethnicity, it has been advocated that supplementary data should be 
registered to provide a more nuanced picture, such as length of stay 
in the country (Rafnsson and Bhopal, 2009). In our study it is possi-
ble to identify accurately whether individuals are born in Denmark 
and whether one of the parents is both born in Denmark and holds 
Danish citizenship, or not. Nevertheless, such a refined background 
classification did not yield stronger associations on use of stat-
ins compared to analysis with simple parameters as birthplace or 
FiguRe 2 | Statin initiation among glucose-lowering medicine users 1997–2006. Kaplan–Meier plots over elapsed time from first glucose-lowering medicine 
(GLM) claim until the first statin claim over a 5-year follow-up period since 1997 (A) and 2001 (B) respectively.
FiguRe 3 | Persistence on statin treatment once initiated in glucose-
lowering medicine users. Proportion of patients receiving glucose-lowering 
medication who were taking statins at any time-point after initiation of statin 
treatment stratified by ethnic origin. Curves end when less than 50 persons 
continue statins.www.frontiersin.org  December 2010  | Volume 1  |  Article 142  |  5
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in communities study (ARIC) population study of cardiovascular 
risk factors among African-American compared to White subjects, 
no differences were found in lipid levels (Hozawa et al., 2007), 
which is also consistent with the review by Kurian et al. of studies 
focusing on the African population (Kurian and Cardarelli, 2007). 
Even though metabolic parameters seem to differ between Eastern 
and Western populations (De Silva et al., 2007; Christensen et al., 
2009; Likhari and Gama, 2009), it is unlikely that the subjects from 
Eastern countries in Denmark have less need of statins as persons 
from certain Eastern countries around the world have been identi-
fied as being at particularly high risk of coronary heart disease and 
of diabetes (McKeigue, 1989; Fischbacher et al., 2009; Gupta et al., 
2009) Hence, subjects from Eastern countries with diabetes living 
in Denmark receive which probably inadequate statin treatment.
Socioeconomic status has previously been associated with statin 
initiation and persistence (Auchincloss et al., 2007; Rasmussen et al., 
2007; Schneeweiss et al., 2007; Jackevicius et al., 2008; Manderbacka 
et al., 2008). In our study we did not find statistically significant 
interactions when stratifying ethnic origin by household income. 
The relatively little impact of income in relation to ethnic origin 
may be due to the general social equality in access to healthcare in 
Denmark, and is in accordance with studies from the US, where 
ethnic differences have been shown to be present while insurance 
coverage is the same (Trivedi et al., 2006). Even extended insur-
ance coverage has not been sufficient to reduce ethnic disparities 
(McWilliams et al., 2009).
This study has some limitations that are important to emphasize. 
An important limitation is the lack of information on individual 
lipid levels. Since diabetes is a high risk factor for cardiovascular 
events (Haffner et al., 1998; Schramm et al., 2008), guidelines rec-
ommend low target lipid levels in all diabetic subjects (NCEP, 2001; 
Buse et al., 2007; Ryden et al., 2007). Most subjects need pharmaco-
logical intervention to reach these goals. Lacking knowledge on lipid 
levels, this study regards only use of statins, which is the first-line 
of medical intervention, and does not address possible indication 
for use of other lipid-lowering medications. Furthermore, we do 
not have information about subjects that were intolerant to treat-
ment or terminated treatment due to side-effects. Nor do we have 
information on subjects with contraindications to treatment with 
statins.
It is important to consider that our ethnical grouping may carry 
some bias that lead to overestimation on the lack of use of statins. 
In spite of broad Danish reimbursement policies, we cannot discard 
that some subjects do purchase medications as GLM and statins in 
their countries of origin.
The US studies have identified limited health literacy and educa-
tion (Parker et al., 2003; Sudore et al., 2006), and mistrust of the 
health care system (Armstrong et al., 2006; Ranjit et al., 2007) as 
important factors for health disparities. We cannot discard that dis-
parities in educational level and psychosocial factors may account 
for the differences in statin use in our cohort. To elucidate this 
question requires further studies.
The advantage of using GLMs to identify diabetes subjects is 
that the indication for treatment is specific for diabetes subjects. 
Hence, this population is well-defined. Nevertheless, use of GLMs 
as a proxy for the diagnosis of diabetes excludes subjects who 
have been diagnosed as having diabetes but who are not using 
FiguRe 4 | Comparison of hazard ratios associated to use of statins 
according to different ethnicity parameters. Comparison of the hazard 
ratios obtained by Cox analysis for discontinuation of statins obtained using 
simple ethnic grouping by citizenship and by country of birth compared with 
refined grouping according to country of origin, obtained by combining 
individual country of birth with the parents’ country of birth.
Table 3 | Cox proportional-hazard analysis of covariates influencing 
discontinuation of statin treatment for 90 days or more in subjects 
receiving glucose-lowering medication.
  Hazard ratio  95% Ci  P
Age – per 10 year  0.85  0.83–0.87  <0.0001
Female sex*  1   
Male sex  1.14  1.10–1.18  0.04
1997–2000*  1  
2001–2003  0.95  0.90–0.99 0.03
2004–2006  0.85 0.82–0.90  <0.0001
No previous myocardial  1     
infarction or stroke
Previous myocardial infarction  0.76  0.64–0.91  <0.0001
Previous stroke  0.70  0.54–0.93  0.004
GLM other than insulin*  1   
Insulin treatment  0.92  0.86–0.92  0.01
CounTRy oF oRigin
 Denmark*  1   
  Western countries**  1.13  1.01–1.28  0.04
  Eastern countries**  2.03  1.91–2.17  <0.0001
 Africa  1.94  1.63–2.32  <0.0001
inCoMe
  Highest quartile*  1   
  Third quartile  1.08  0.90–1.28  0.4
  Second quartile  1.17  1.00–1.37  0.05
  Lowest quartile  1.24  1.05–1.46  0.01
*Reference in Cox regression analysis.
**Western countries include America, Oceania, Baltic countries, and Western 
Europe. Eastern countries include Asia and Turkey.Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology  December 2010  | Volume 1  |  Article 142  |  6
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